Raymond James Financial Services Advisors, Inc. Vericel Corp Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$35.2 - $52.6 $439,401 - $656,605	-12,483 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$46.35 - $59.75 $11,124 - $14,340	-240 Reduced 1.89%	12,483 $609,000
Q2 2021 Aug 11, 2021	BUY	$47.2 - $67.81 $169,731 - $243,844	3,596 Added 39.4%	12,723 $668,000
Q1 2021 May 14, 2021	SELL	$30.93 - $59.48 $46,116 - $88,684	-1,491 Reduced 14.04%	9,127 $507,000
Q4 2020 Feb 12, 2021	SELL	$18.53 - $31.5 $49,864 - $84,766	-2,691 Reduced 20.22%	10,618 $328,000
Q3 2020 Nov 04, 2020	SELL	$14.68 - $19.12 $22,944 - $29,884	-1,563 Reduced 10.51%	13,309 $247,000
Q2 2020 Jul 17, 2020	BUY	$8.5 - $15.82 $126,412 - $235,275	14,872 New	14,872 $206,000
Q1 2020 Apr 21, 2020	SELL	$7.25 - $19.22 $150,524 - $399,045	-20,762 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$13.77 - $19.2 $35,196 - $49,075	-2,556 Reduced 10.96%	20,762 $361,000
Q3 2019 Nov 07, 2019	SELL	$14.93 - $19.83 $61,227 - $81,322	-4,101 Reduced 14.96%	23,318 $353,000
Q2 2019 Aug 06, 2019	BUY	$15.01 - $18.89 $67,424 - $84,853	4,492 Added 19.59%	27,419 $518,000
Q1 2019 May 06, 2019	BUY	$16.23 - $20.29 $31,891 - $39,869	1,965 Added 9.37%	22,927 $401,000
Q4 2018 Feb 11, 2019	SELL	$10.77 - $18.44 $146,708 - $251,189	-13,622 Reduced 39.39%	20,962 $365,000
Q3 2018 Nov 14, 2018	SELL	$9.1 - $14.8 $142,615 - $231,945	-15,672 Reduced 31.18%	34,584 $489,000
Q2 2018 Jul 30, 2018	BUY	$9.6 - $14.6 $482,457 - $733,737	50,256 New	50,256 $487,000

Others Institutions Holding VCEL

# of Institutions

293

Shares Held

50.7M

Call Options Held

98.2K

Put Options Held

135K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.18B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account